| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3903243 | Urology | 2008 | 5 Pages |
Abstract
The risk for cancer after HGPIN diagnosis (21.5%) was not higher than the risk reported after BPT diagnosis (23.0%). PSA and HGPIN focality at biopsy do not enhance cancer predictivity. Patients with a HGPIN diagnosis do not seem to need any different follow-up rebiopsy strategy than patients with a BPT diagnosis.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Fabrizio Gallo, Luciano Chiono, Emilio Gastaldi, Ezio Venturino, Claudio Giberti,